2026-04-27T07:54:48Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/181402024-02-12T19:47:43Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Cismaru, Anca Liliana
author
Rudin, Deborah
author
Ibañez, Luisa
author
Liakoni, Evangelia
author
Bonadies, Nicolas
author
Kreutz, Reinhold
author
Carvajal, Alfonso
author
Lucena, Maria Isabel
author
Martin, Javier
author
Sancho Ponce, Esther
author
Molokhia, Mariam
author
Eriksson, Niclas
author
EuDAC Collaborators,
author
Krähenbühl, Stephan
author
Largiadèr, Carlo R
author
Haschke, Manuel
author
Hallberg, Pär
author
Wadelius, Mia
author
Amstutz, Ursula
2024-02-12T19:47:43Z
2024-02-12T19:47:43Z
2020-10-29
http://hdl.handle.net/10668/16529
http://hdl.handle.net/20.500.12105/18140
33138277
10.3390/genes11111275
2073-4425
Genes
Agranulocytosis is a rare yet severe idiosyncratic adverse drug reaction to metamizole, an analgesic widely used in countries such as Switzerland and Germany. Notably, an underlying mechanism has not yet been fully elucidated and no predictive factors are known to identify at-risk patients. With the aim to identify genetic susceptibility variants to metamizole-induced agranulocytosis (MIA) and neutropenia (MIN), we conducted a retrospective multi-center collaboration including cases and controls from three European populations. Association analyses were performed using genome-wide genotyping data from a Swiss cohort (45 cases, 191 controls) followed by replication in two independent European cohorts (41 cases, 273 controls) and a joint discovery meta-analysis. No genome-wide significant associations (p
eng
Dipyrone
Drug-induced agranulocytosis
Genome-wide association study
Metamizole
Pharmacogenetics
Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations.
research article